Fibroblast-targeted Drugs and Imaging for Improved Internalization and Retention

Back to all technologies
Download as PDF
2019-LOW-68689
Medical imaging to detect tumors has unfortunately led to limited success in internalization of ligand targeted drugs as well as high rates of tumor retention following cancer treatments. In order to increase avidity for Fiber Activated Proteins (FAP) while focusing on patient comfort, researchers at Purdue University have created an imaging agent for tumor microenvironments that utilizes multivalent and covalent inhibitor based ligand targeted drug conjugates. The novel solution distinguishes more accurately between healthy cells and overexpressed FAPs for controlled drug targeting, eliminating the likelihood of occurrence for cell damage. In addition, it facilitates wound healing post-surgery for cancer treatment. The therapeutic Cancer Associated Fibroblast (CAF) method also alleviates fibrotic diseases.

Advantages:
-Maintains more healthy cells during cancer therapy
-Improved internalization rate
-Lower tumor retention rate

Potential Applications:
-Imaging tumor microenvironments
-Targeting drug delivery for cancer therapy
-Treatment of fibrosis and fibrotic diseases
Aug 20, 2020
Provisional-Patent
United States
(None)
(None)

Jul 17, 2019
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org